Tagged with GE

Clinical trials The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science behind Traditional Chinese Medicine. What is the vision behind Vita Genomics? Vita Genomics was founded in 2001. At the time,…

Generics Janssen has historically had a very strong focus on emerging markets. In today’s world, where growth for the pharmaceutical industry overwhelmingly comes from emerging markets, where do we find the Nordics?  What is the relevance of the Nordics for the country’s global footprint?  Jansen has preserved the cluster model. We…

GGD The co-managing partner of one of Canada’s leading IP law firms discusses the landscape for intellectual property in the pharmaceutical industry in Canada today, the legislative challenges facing his clients, and the incentive schemes in place to bring innovation to Canada.  What have you seen as the key trends of…

Generics Calvin Tsai and Jack Wu talk about their two-pronged international approach through pharmaceuticals and nutricare. The head of the nutricare business elaborates on the challenge of introducing milk products to the Asian market in the current climate, and the head of the pharma business explains the company’s long-term strategy for…

Generics A perspective on Indonesia’s booming market for contraceptive products from Hendra Gunawan, managing director of PT Tunggal Idaman Abdi, one of Indonesia’s leading players in the sector. To cope with the growing demand for contraceptive driven by 65 million women of reproductive age, the company is building a second hormone…

Generics Tom Rönnlund discusses the current state of the pharmaceutical industry in the Nordics in this time of austerity, and offers opinions on reference pricing and cooperation in the region. How have the markets in Denmark and Sweden evolves over the past five years, since the financial crisis started and austerity…

Ireland   What makes Ireland attractive for FDI? As the former general manager of Genzyme’s Waterford site, Pat O’Sullivan explains that a longstanding 12.5% corporate tax rate (that isn’t going anywhere) is one factor, but it doesn’t end there. Talent: “The first factor is the excellence of the workforce, which is…

Contract Manufacturing It is widely acknowledged that pharmaceutical manufacturing operations have entered into a period of significant cost reduction. Service providers like Dalkia—a French energy services company that has built its Irish business upon serving the pharmaceutical sector—have had to help clients cope. Dalkia Ireland’s managing director Pat Gilroy remembers his years…

Clinical trials The chairman and CEO of Medigen shares his insights on a significant past three years for the company, which included both an IPO and major developments for the company’s innovative molecule PI-88. He also offers his perspective on the increasing synergies between Taiwan and China in the biotech sector. During our…

Generics Fergal Murphy, Chairman of the Association of Pharmaceutical Manufacturers in Ireland, discusses with pharamaboardroom.com the difficulties in such a small market and how the industry is adapting to the needs of Ireland by working closely with the government to find the right price point for products and increasing awareness of…

Biogen Idec Having experienced many years at big pharmaceutical companies, you moved into the biotech sector by joining Biogen Idec late 2010. What made you decide to switch? To me, it was an easy decision. It was an appealing challenge to join a company that was in growth mode but where many…

Generics Eric Ng received his degree at National University of Singapore. In his career he has worked for such companies as AstraZeneca before moving to Sanofi-Aventis China until his rise in rank to President Director of Sanofi in Indonesia. Today he talks about the stiff competition in Indonesia in the generics…